Skip to Main Content
Skip Nav Destination

Groundbreaking TIL Therapy OK’d for Melanoma

February 21, 2024

Abstract: After decades of research, the first tumor-infiltrating lymphocyte therapy was greenlighted by the FDA to treat patients with inoperable or metastatic melanoma—Iovance’s lifileucel (Amtagvi). The agency’s approval is not only the first for a cellular immunotherapy but also for a solid tumor. 


You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal